Abstract 1494P
Background
Patients (pts) with metastatic NSCLC often present ECOG-PS 2+ at diagnosis. Identifying those pts with a life expectancy ≤ 90 d allows for early referral to palliative care and favors better adequacy of resources. This study aimed to characterize those factors associated with an overall survival (OS) < 90 d. (ClinicalTrials.gov: NCT04306094).
Methods
It is a prospective cohort study (Nov/17 – Jun/23). All eligible pts met the following criteria: ≥ 18 y.o.; treatment-naive, histologically proven NSCLC stages IVA-IVB; ECOG-PS 2-4; no other cancer, and were consecutively included after signing informed consent. We collected 83 baseline features, including, but not restricted to, demographics, histology, EGFR-mutational status, medical history, nutritional status and body composition, smoking status, symptom burden, palliative scores, and laboratory values. We defined cachexia as published by Fearon et al. (2011). Logistic regression (LR) was performed to adjust prognostic factors related to OS < 90 d. The Hosmer-Lemeshow test was conducted to assess the goodness of fit of the LR model.
Results
180 pts were included: median age was 67 y.o. (18-86), 58% were male, and 152 pts (84%) were current/previous smokers. In terms of ECOG-PS, 107 presented PS2 (59%), 57 PS3 (32%), and 16 PS4 (9%). Adenocarcinoma was the most common histology (61%, EGFR mut in 16 pts), followed by squamous histology (26%). CNS metastases were detected in 40 pts (22%) and liver involvement in 17 pts (9%). Median OS was 87 d, and 91 pts (51%) had OS < 90 d. According to ECOG-PS, mOS was 106 d (PS2), 55 d (PS3) and 24 d (PS4) (p
Conclusions
In this cohort of pts, Hb level, PAP score, use of supplemental O2, presence of cachexia and ECOG-PS 3-4 were important determinants of OS < 90 d. Prognostic models incorporating these factors should be developed to improve OS estimation in these pts.
Clinical trial identification
NCT04306094.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. De Castro Jr.: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, TEVA, Lilly; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Libbs, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, TEVA, Yuhan, Sanofi; Financial Interests, Local PI: Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Roche; Financial Interests, Steering Committee Member: AstraZeneca, Bayer, Beigene, Merck Sharp & Dohme; Financial Interests, Personal, Steering Committee Member: GSK, Novartis; Financial Interests, Institutional, Local PI: Lilly, Pfizer, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1491P - Palliative care of E-warm model for driver-gene-negative non-small cell lung cancer patients: A single-center randomized controlled trial
Presenter: Junhui Zhang
Session: Poster session 10
Resources:
Abstract
1492P - The role of LACE index in predicting 30-day unplanned readmission in patients receiving immunotherapy
Presenter: Duygu Ercan Uzundal
Session: Poster session 10
1493P - The Italian version of the FAMCARE-P13 questionnaire: A validation study
Presenter: Giacomo Massa
Session: Poster session 10
1495P - Impact of social isolation on the clinical outcomes in advanced NSCLC patients
Presenter: Yoh Yamaguchi
Session: Poster session 10
1496P - Predictors of early mortality after hemodialysis in patients with cancer and acute kidney injury
Presenter: Suleyman Cagin Gurbuz
Session: Poster session 10
1497P - Resuscitation decisions in advanced cancer: A mixed methods study exploring survival outcomes and views of healthcare professionals
Presenter: Rachel Prichard
Session: Poster session 10
1498P - Acute myeloid leukemia: Trends in palliative care utilization in hospitalized patients over 65 years old - A national inpatient sample study (2016-2020)
Presenter: Marco Bermudez
Session: Poster session 10
Resources:
Abstract
1499P - Knowledge, attitudes, and current practices toward lung cancer palliative care management in China: A national survey
Presenter: Mengting Chen
Session: Poster session 10
Resources:
Abstract
1500P - Caring for carers: The impact of death & dying on doctors-in-training in an Irish tertiary referral hospital
Presenter: Conor Moloney
Session: Poster session 10
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10